COST-EFFECTIVENESS OF IDELALISIB IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN PORTUGAL

被引：0
|
作者：
Silva, M. G. [1 ]
Gouveia, M. [2 ]
Alarcao, J. [3 ]
Fiorentino, F. [3 ]
Carda, J. [4 ]
Costa, R. M. [5 ]
Mariz, J. M. [1 ]
Raposo, J. [6 ]
Borges, M. [3 ]
机构：
[1] Inst Portugues Oncol Francisco Gentil, Lisbon, Portugal
[2] Catolic Lisbon Sch Business & Econ, Lisbon, Portugal
[3] Univ Lisbon, Ctr Evidence Based Med, Fac Med, P-1699 Lisbon, Portugal
[4] Ctr Hosp Univ Coimbra, Coimbra, Portugal
[5] Hosp Garcia de Orta, Lisbon, Portugal
[6] Ctr Hosp Lisboa Norte, Lisbon, Portugal
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1439
引用
收藏
页码：577 / 577
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF IDELALISIB IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN PORTUGAL
    Gouveia, M.
    Silva, M. G.
    Alarcao, J.
    Fiorentino, F.
    Carda, J.
    Costa, R.
    Mariz, J. M.
    Raposo, J.
    Costa, J.
    Borges, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A461 - A462
  • [2] Cost-Effectiveness of Venetoclax and Rituximab Combination Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in Argentina
    Elgart, Jorge Federico
    Glancszpigel, Mariana
    Kanevsky, Diego
    Godar, Maria
    Touliet, Valeria
    Albaytero, Natalia
    [J]. BLOOD, 2019, 134
  • [3] COST-UTILITY OF IDELALISIB IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Casado, L. F.
    Hernandez, J. A.
    Jarque, I
    Echave, M.
    Casado, M. A.
    Castro-Gomez, A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A557 - A557
  • [4] Cost-effectiveness analysis of idelalisib-rituximab in relapsed or refractory CLL
    Marchetti, Monia
    Cuneo, Antonio
    Montillo, Marco
    Romana, Mauro Francesca
    Martelli, Elisa
    Pedone, Maria Paola
    [J]. LEUKEMIA & LYMPHOMA, 2015, 56 : 117 - 118
  • [5] COST-EFFECTIVENESS OF IBRUTINIB AND RITUXIMAB FOR THE RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN CHINA
    Yang, F.
    Kumar, A.
    Rojanasarot, S.
    Schommer, J. C.
    Shao, R.
    [J]. VALUE IN HEALTH, 2018, 21 : S31 - S31
  • [6] Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
    Michaela Barbier
    Nicholas Durno
    Craig Bennison
    Mathias Örtli
    Christian Knapp
    Matthias Schwenkglenks
    [J]. The European Journal of Health Economics, 2022, 23 : 837 - 846
  • [7] Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
    Barbier, Michaela
    Durno, Nicholas
    Bennison, Craig
    Ortli, Mathias
    Knapp, Christian
    Schwenkglenks, Matthias
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2022, 23 (05): : 837 - 846
  • [8] COST-EFFECTIVENESS OF VENETOCLAX AND RITUXIMAB COMBINATION THERAPY VERSUS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) IN COLOMBIA
    Chacon-Acevedo, K. R.
    Gamboa, O.
    Quitian Reyes, D.
    [J]. VALUE IN HEALTH, 2020, 23 : S37 - S37
  • [9] A SCOTLAND BASED COST-EFFECTIVENESS ANALYSIS OF IDELALISIB (ZYDELIG®) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF ADULTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA CLL)
    Kumar, G.
    Morton, T. D.
    Padhiar, A.
    Marsh, R.
    Perard, R.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A455 - A455
  • [10] Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    Coutre, Steven E.
    Flinn, Ian W.
    de Vos, Sven
    Barrientos, Jacqueline C.
    Schreeder, Marshall T.
    Wagner-Johnson, Nina D.
    Sharman, Jeff P.
    Boyd, Thomas E.
    Fowler, Nathan
    Dreiling, Lyndah
    Kim, Yeonhee
    Mitra, Siddhartha
    Rai, Kanti
    Leonard, John P.
    Furman, Richard R.
    [J]. HEMASPHERE, 2018, 2 (03):
12345